|
gptkbp:instanceOf
|
antipsychotic medication
|
|
gptkbp:administeredBy
|
intramuscular injection
oral tablet
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:associatedWith
|
gptkb:clozapine
gptkb:quetiapine
gptkb:risperidone
|
|
gptkbp:ATCCode
|
gptkb:N05AH03
|
|
gptkbp:blackBoxWarning
|
increased risk of death in elderly patients with dementia-related psychosis
|
|
gptkbp:CASNumber
|
gptkb:132539-06-1
|
|
gptkbp:category
|
mood stabilizer
psychiatric medication
second-generation antipsychotic
|
|
gptkbp:chemicalFormula
|
gptkb:C17H20N4S
|
|
gptkbp:contraindication
|
hypersensitivity to olanzapine
|
|
gptkbp:drugClass
|
antipsychotic medication
|
|
gptkbp:eliminatedIn
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
intramuscular injection
orally disintegrating tablet
|
|
gptkbp:genericName
|
gptkb:olanzapine
|
|
gptkbp:halfLife
|
21 to 54 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zyprexa
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketedAs
|
1996
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2011
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
gptkb:diabetes_mellitus
gptkb:metabolic_syndrome
dyslipidemia
increased mortality in elderly with dementia-related psychosis
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
constipation
weight gain
drowsiness
dry mouth
extrapyramidal symptoms
increased appetite
hyperglycemia
|
|
gptkbp:usedFor
|
bipolar disorder
schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:礼来
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:bfsLayer
|
5
|